Longeveron Inc. (LGVN) stock
LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.92−0.19 (-9.00%)
Close on Nov 18, 2026Market cap $61.21MP/E –Yield –
Longeveron total assets
Total assets on the balance sheet at the end of each period.
Longeveron's total assets was $15.49M at Jun 30, 2026. For fiscal 2025 it was $10.26M, down 59.9% from the year before. The highest annual figure on record is $42.77M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.26M | -59.9% |
| FY2024 | Dec 31, 2024 | $25.56M | +111.6% |
| FY2023 | Dec 31, 2023 | $12.08M | -55.9% |
| FY2022 | Dec 31, 2022 | $27.41M | -35.9% |
| FY2021 | Dec 31, 2021 | $42.77M | +362.8% |
| FY2020 | Dec 31, 2020 | $9.24M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $15.49M | -7.5% |
| Q1 FY2026 | Mar 31, 2026 | $21.21M | +1.7% |
| Q4 FY2025 | Dec 31, 2025 | $10.26M | -59.9% |
| Q3 FY2025 | Sep 30, 2025 | $15.56M | -48.0% |
| Q2 FY2025 | Jun 30, 2025 | $16.75M | -13.6% |
| Q1 FY2025 | Mar 31, 2025 | $20.85M | +115.0% |
| Q4 FY2024 | Dec 31, 2024 | $25.56M | +111.6% |
| Q3 FY2024 | Sep 30, 2024 | $29.91M | +157.3% |
| Q2 FY2024 | Jun 30, 2024 | $19.39M | +13.5% |
| Q1 FY2024 | Mar 31, 2024 | $9.70M | -55.5% |
| Q4 FY2023 | Dec 31, 2023 | $12.08M | -55.9% |
| Q3 FY2023 | Sep 30, 2023 | $11.63M | -67.1% |
| Q2 FY2023 | Jun 30, 2023 | $17.09M | -56.4% |
| Q1 FY2023 | Mar 31, 2023 | $21.81M | -49.0% |
| Q4 FY2022 | Dec 31, 2022 | $27.41M | +1.0% |
| Q2 FY2022 | Jun 30, 2022 | $35.33M | +18.3% |
| Q1 FY2022 | Mar 31, 2022 | $39.17M | +20.8% |
| Q4 FY2021 | Dec 31, 2021 | $42.77M | +362.8% |
| Q3 FY2021 | Sep 30, 2021 | $27.15M | – |
| Q2 FY2021 | Jun 30, 2021 | $29.86M | – |
| Q1 FY2021 | Mar 31, 2021 | $32.43M | – |
| Q4 FY2020 | Dec 31, 2020 | $9.24M | – |
See a number that looks wrong?